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Abstract
Objective—Diuretics are often prescribed off-label to premature infants, particularly to prevent 
or treat bronchopulmonary dysplasia (BPD). We examined their use and safety in this group.
Study Design—Retrospective cohort study of infants <32 weeks gestation and <1500 g birth 
weight exposed to diuretics in 333 neonatal intensive care units from 1997–2011. We examined 
use of acetazolamide, amiloride, bumetanide, chlorothiazide, diazoxide, ethacrynic acid, 
furosemide, hydrochlorothiazide, mannitol, metolazone, or spironolactone combination. 
Respiratory support and FiO2 on the first day of each course of diuretic use were identified.
Results—Thirty-seven percent (39,357/107,542) of infants were exposed to at least 1 diuretic; 
furosemide was the most commonly used (93% with ≥1 recorded dose), followed by 
spironolactone, chlorothiazide, hydrochlorothiazide, bumetanide, and acetazolamide. Seventy-four 
percent were exposed to 1 diuretic at a time, 19% to 2 diuretics simultaneously, and 6% to 3 
diuretics simultaneously. The most common combination was furosemide/spironolactone, 
followed by furosemide/chlorothiazide and chlorothiazide/spironolactone. Many infants were not 
receiving mechanical ventilation on the first day of each new course of furosemide (47%), 
spironolactone (69%), chlorothiazide (61%), and hydrochlorothiazide (68%). Any adverse event 
occurred on 42 per 1000 infant-days for any diuretic and 35 per 1000 infant-days for furosemide. 
Any serious adverse event occurred in 3.8 for any diuretic and 3.2 per 1000 infant-days for 
furosemide. The most common laboratory abnormality associated with diuretic exposure was 
thrombocytopenia.
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Conclusion—Despite no FDA indication and little safety data, over one third of premature 
infants in our population were exposed to a diuretic, many with minimal respiratory support.
Keywords
bronchopulmonary dysplasia; diuretic; safety; drug
Premature infants in the neonatal intensive care unit (NICU) are frequently exposed to 
diuretics presumably to treat or prevent bronchopulmonary dysplasia (BPD).1,2 BPD is the 
most common pulmonary morbidity of prematurity; it is caused by prolonged mechanical 
ventilation and exposure to oxygen, and the strongest risk factor is prematurity.3,4 Because 
BPD is associated with serious long-term consequences, including neurodevelopmental 
impairment,5 neonatologists use drugs such as diuretics in an attempt to reduce the incidence 
of BPD or improve BPD symptoms.
The rationale for diuretic use is based on the physiology of premature infants in the first 
postnatal weeks. Failure to lose weight, usually due an excessive administration of fluid 
and/or sodium, during that time is associated with an increased risk of BPD.6,7 Because 
premature infants are born with an abundance of extracellular fluid (including both free 
water and sodium), neonatologists use diuretics to potentiate the naturally occurring weight 
loss. This rationale extends beyond the first postnatal weeks to chronic administration (>1 
month) of diuretics to decrease pulmonary edema and improve lung compliance and 
oxygenation.1,2 This approach may reduce exposure to mechanical ventilation and the 
incidence of BPD. However, no diuretic is FDA-approved to prevent or treat BPD in 
premature infants. Cochrane reviews on loop and distal renal tubule diuretics demonstrate 
short-term (usually <1 week) improvement of pulmonary mechanics and oxygenation.1,2 
Unfortunately, none of the available studies demonstrated improvements in BPD, duration 
of mechanical ventilation, or hospital stay.1,2
Given the known risks and potential benefits of diuretics, we sought to describe the current 
use of diuretics in this population. Identifying and describing the most commonly used 
diuretics may be helpful to determine potential trial targets. We examined premature infant 
exposure to common diuretics, the respiratory support that premature infants received at the 
time of diuretic use, and the safety of diuretics in premature infants.
Methods
Study design and setting
We performed a retrospective cohort study of infants <32 weeks gestational age (GA) and 
<1500 g birth weight discharged from one of 333 NICUs managed by the Pediatrix Medical 
Group between 1997 and 2011 who were exposed to at least 1 diuretic of interest 
(acetazolamide, amiloride, bumetanide, chlorothiazide, diazoxide, ethacrynic acid, 
furosemide, hydrochlorothiazide, mannitol, metolazone, spironolactone). The dose of 
medications is not consistently recorded in the database. We collected demographic data, 
discharge data, laboratory values, and respiratory support information. The study was 
approved by the Duke University Institutional Review Board.
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We used counts and proportions to describe diuretic use by 3 different methods. We defined 
exposure as any exposure to a unique diuretic for each infant. We defined diuretic course as 
the number of times an infant was exposed to a unique diuretic. To be counted as a new 
course, each diuretic exposure had to be separated from the prior exposure to the same 
diuretic in the same infant by >1 day. We defined days of exposure as the number of days 
each unique diuretic was administered to each infant. We defined a simultaneous diuretic 
combination as 2 diuretics reported on the same day at least once for each infant and total 
number of days of simultaneous diuretic exposure.
We identified the level of respiratory support provided on the start day of each new diuretic 
course. Respiratory support was classified as the highest level of support required by an 
infant on a given day: room air only, nasal cannula, high-flow nasal cannula/nasal 
continuous positive airway pressure, conventional mechanical ventilation, and high-
frequency mechanical ventilation. We also report the highest daily fraction of inspired 
oxygen (FiO2) received on the start day of each new diuretic course.
Available laboratory information was collected while infants were exposed to diuretics. A 
laboratory value was included in this report if it occurred between the start of exposure 
through the end of exposure to a diuretic. Laboratory abnormalities were classified as an 
adverse event (AE) or serious adverse event (SAE) based on pre-specified cut-off 
values.8We defined renal stones as an AE if a diagnosis of nephrocalcinosis or 
nephrolithiasis was made after the first exposure to any diuretic, even if the diuretic was 
discontinued. We examined outcomes for all diuretics and for those infants exposed to 
furosemide, because it was by far the most common diuretic used. Because hearing tests 
were not consistently recorded in the database, we did not examine the association between 
diuretic exposure and hearing loss.
Statistical analysis
Standard summary statistics were used to describe demographic characteristics; continuous 
variables are presented as median (25th and 75th percentiles), and categorical variables are 
presented as counts (proportions). Laboratory AEs and SAEs were described at the infant 
day level (number of days with abnormal laboratory values/1000 infant days exposed to 
diuretics). The proportion of infants exposed to diuretics over time was calculated by 
dividing the number of infants exposed to diuretics by the total number of infants discharged 
from the Pediatrix Medical Group in the same year. The proportion of infants exposed to 
diuretics by GA is calculated by dividing the number of infants exposed to diuretics by the 
total number of infants of the same GA. The proportion of infants exposed to diuretics by 
NICU is calculated by dividing the number of infants exposed to diuretics by the total 
number of infants discharged from each NICU during the study period. Note that only 
NICUs with an average of >10 very low birth weight infant discharges per year were 
included in the analysis of diuretic usage by site. All statistical analyses were performed in 
STATA 12.0 (College Station, TX).
Laughon et al. Page 3























We identified 107,542 infants meeting birth weight and GA criteria between 1997 and 2011. 
Of these, 39,357 (37%) infants were exposed to at least 1 diuretic (Table 1). Exposed infants 
had a lower median GA (27 weeks [25th, 75th% -tile; 25, 28] vs. 29 weeks [27, 30], 
p<0.001) and lower median birth weight (870 g [700, 1085] vs. 1115 g [865, 1310], 
p<0.001) compared with infants not exposed. Of the infants exposed to diuretics, 25,975 
(66%) were extremely low birth weight (<1000 g birth weight). The median length of 
diuretic exposure was 6 days (2, 24 days). The median postnatal day that the first course of 
diuretics was started was 18 (9, 33). Among those infants exposed to a diuretic, the majority 
were exposed for <28 days (30,528; 78%). The use of diuretics increased from 29% of 
infants in 1997 to 39% in 2005 (Fig. 1) and remained relatively stable after that time (36% 
in 2011). The median diuretic exposure by site was 33%, ranging from 0–75% (Fig. 2).
Of the 39,357 infants exposed to at least 1 diuretic during their stay, furosemide was the 
most commonly used, with 36,759 (93%) of infants with at least 1 recorded dose (Table 2). 
Furosemide also represented the most frequent number of courses (784 per 1000 infants) and 
days of use (66 per 1000 infant days). The next most commonly used diuretics were 
spironolactone, chlorothiazide, hydrochlorothiazide, bumetanide, and acetazolamide (Table 
2). Of the infants exposed to a diuretic, 29,144 (74%) were exposed to 1 diuretic at a time; 
7576 (19%) were exposed to 2 different diuretics simultaneously; 2554 (6%) were exposed 
to 3 diuretics simultaneously; and 83 (0.2%) were exposed to 4 or more diuretics 
simultaneously. The most common combination of diuretics was furosemide + 
spironolactone (40 per 1000 infants, Table 3), followed by furosemide + chlorothiazide (36 
per 1000 infants), then chlorothiazide + spironolactone (36 per 1000 infants).
Overall, the majority of infants were receiving some form of respiratory support on the first 
day of diuretic therapy. Many infants were not receiving mechanical ventilation on the first 
day of each new diuretic course for the most commonly used diuretics (Table 4). However, 
only 8% of infants exposed to bumetanide were not receiving mechanical ventilation. The 
median FiO2 on the first day of a new course of diuretics was similar across most drugs, but 
was highest for bumetanide at 0.45 (0.30, 0.75).
AEs occurred on 42 per 1000 infant days for any diuretic and 35 per 1000 infant days for 
furosemide. SAEs occurred on 3.8 per 1000 infant days for any diuretic and 3.2 per 1000 
infant days for furosemide (Table 5). The most common laboratory abnormality associated 
with diuretic exposure was thrombocytopenia. The most common electrolyte abnormality 
noted was hyperkalemia: the AE level was 12.7 per 1000 infant days for any diuretic and 8.3 
per 1000 infant days for furosemide; the SAE level was 1.6 and 1.2 per 1000 infant days, 
respectively. We found that elevated blood urea nitrogen occurred on 3.7 and 3.1 per 1000 
infant days for any diuretic and for furosemide, respectively; an elevated creatinine was 
observed on 5.4 and 4.3 per 1000 infant days for any diuretic and for furosemide, 
respectively. Markers of liver damage (aspartate aminotransferase/alanine aminotransferase 
[AST/ALT]) were rarely increased, while elevated direct bilirubin (9.9 per 1000 infant days 
for any diuretic and 6.6 per 1000 infant days for furosemide) was more frequently noted. 
Renal stones were reported in 1.0% of infants exposed to any diuretic and most commonly 
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in infants exposed to acetazolamide (39/1131; 3.5%), followed by hydrochlorothiazide 
(74/2326; 3.2%).
Discussion
Neonatologists frequently expose premature infants to diuretics without evidence of long-
term benefits. We found that over one third of premature infants <32 weeks gestation at 
birth and <1500 g birth weight received diuretic therapy during their hospital stay, often for 
more than a month. Furosemide was by far the most commonly used diuretic in this 
population, followed by spironolactone and chlorothiazide. These findings are consistent 
with previous research.9 The majority of infants receive only 1 type of diuretic during their 
admission; however, nearly a third received combination therapy with 2 or more diuretics. 
The majority of diuretic use was likely designed to reduce the risk of BPD or treat BPD 
symptoms.
BPD is associated with early pulmonary edema localized to the alveoli and interstitium.10,11 
Diuretics improve this edema by removing excess fluid, allowing for improved gas 
exchange and decreased respiratory support requirements.12 Because mechanical ventilation 
is a strong risk factor for BPD, improving pulmonary mechanics theoretically would result 
in decreased incidence of BPD. Despite the sound physiologic rationale behind the use of 
diuretics in preventing BPD and evidence to demonstrate short-term improvement, evidence 
for long-term benefits, such as prevention of BPD, is lacking.1,2,12 In addition, it is uncertain 
which subgroup of premature infants (e.g., what GA or level of respiratory support) might 
benefit from exposure to diuretics.
The search for therapeutics to treat or prevent BPD has been extensive but with limited 
success. There are no FDA-indicated therapies that prevent BPD or are available to treat 
BPD symptoms. To date, only vitamin A and caffeine prevent BPD without known 
significant long-term AEs.13,14 Postnatal steroids reduce BPD but may increase the risk of 
cerebral palsy.15 Although inhaled nitric oxide is beneficial in term infants with hypoxic 
respiratory failure, the majority of studies demonstrate that it does not prevent BPD in 
premature infants, although there was a great deal of heterogeneity in the patient 
populations, dose, and duration of inhaled nitric oxide.16 Currently, a study in premature 
infants that emulates the largest successful trial of inhaled nitric oxide17 has completed 
recruitment; data analysis is ongoing (clinicaltrials.gov NCT00931632). One problem with 
the vast majority of trials of drugs to prevent BPD is that they did not establish the 
pharmacokinetics, pharmacodynamics, or dose prior to implementation of phase III, 
randomized, controlled trials.18
Diuretics are used in the NICU “off-label,” meaning that there is no FDA indication for use 
in infants. The use of off-label medications is associated with increased risk of AEs, 
particularly in sick hospitalized infants.19–22 Neonatal medicine’s history is plagued with 
examples of SAEs with inadequate study and approval before widespread implementation of 
therapies.23–26 While more evidence is required for safe use of diuretics in neonates, trials in 
this population are difficult. Vulnerable populations (e.g., premature neonates) have an 
especially low parental consent rate.27 Randomized controlled trials, while the gold standard 
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for new drugs, are expensive and time consuming, making it challenging to find support for 
therapeutics, such as diuretics, that are off-patent generic drugs. Many pediatricians are very 
familiar with using medications off-label due to limited data and rely heavily on their 
personal clinical experience.28,29 Clinical experience bias may further limit the willingness 
of physicians to withhold or limit diuretics for premature infants at risk for BPD, as in the 
placebo group in a prospective trial.
We found that exposure of premature infants to diuretics varied widely across sites, which is 
consistent with previous research demonstrating that a range of 4–86% of infants with BPD 
receiving a >5 day course of diuretics, depending on the center.9 In some centers, we found 
that the exposure was very high, suggesting that diuretics are used prophylactically, 
presumably to prevent BPD. Conversely, in other centers, exposure was rare. These 
observations suggest that there is no universally accepted standard of care for when to 
expose infants to diuretics and that no exposure is an option exercised in some centers.
The strengths of this study include the large sample size. This cohort includes data on 
infants from 333 NICUs across North America, including both academic and community 
sites, allowing these results to be generalizable to many institutions as well as a wide range 
of NICU populations. However, the study was limited by the lack of indication for the 
diuretic exposure. Thus, clinicians may have, and likely did, use diuretics for a variety of 
indications, including attempting to reduce FiO2 for infants on a low amount of oxygen (e.g., 
an infant receiving 0.1 L/min of 100% FiO2 a week or two prior to anticipated discharge), 
post-operative fluid changes, following blood product administration, or renal insufficiency. 
In addition, laboratory values were not obtained uniformly, thus sicker infants—who 
presumably may have more laboratory draws—may have contributed more data to these 
values. Finally, AEs and SAEs reported were not necessarily caused by diuretic use. These 
premature infants have multiple other physiologic derangements that may have led to these 
observations.
While there are many challenges—including common use, low consent rates, and other 
aspects of study design—further studies must be conducted to ensure that diuretics are safe 
and effective in premature infants.
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Percentage of infants <32 weeks and <1500 g exposed to diuretics over time.
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Percentage of infants <32 weeks and <1500 g exposed to (A) furosemide and (B) any 
diuretic by site.
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Table 2
Infants <32 Weeks and <1500 g Exposed to Diuretics by Type
Diuretic* N (%)† Exposure‡ Courses‡ Days of exposure§
Total N=39,357
Furosemide 36,759 (93) 342 784 66
Spironolactone 9577 (24) 86 109 3
Chlorothiazide 8309 (21) 77 98 29
Hydrochlorothiazide 2473 (6) 22 26 7
Bumetanide 1443 (4) 13 17 2
Acetazolamide 1131 (3) 11 18 2
*
Metolazone (n=147), hydrochlorothiazide/spironolactone (n=87), diazoxide (n=64), ethacrynic acid (n=61), mannitol (n=8), and amiloride (n=3) 
exposures were minimal.
†
Infants could be exposed to more than 1 diuretic.
‡
Per 1000 infants (all infants).
§
Per 1000 infant days (all infants).
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Table 3
Top 10 Simultaneous Diuretic Combinations in Infants <32 Weeks and <1500 g
Rank Diuretic combination Exposure* Days of
simultaneous
exposure†
1 Chlorothiazide + spironolactone 36 12
2 Hydrochlorothiazide+ spironolactone 13 4.4
3 Furosemide + spironolactone 40 2.9
4 Furosemide + chlorothiazide 36 2.6
5 Furosemide + hydrochlorothiazide 11 0.9
6 Furosemide + bumetanide 8 0.6
7 Furosemide + acetazolamide 5 0.8
8 Acetazolamide + spironolactone 2 0.3
9 Chlorothiazide + acetazolamide 1 0.1
10 Hydrochlorothiazide + acetazolamide 0.7 0.1
*
For at least one day, per 1000 infants (all infants).
†
Per 1000 infant days (all infants).
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